These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 10557040)

  • 1. Clinical relevance of minimal residual disease monitoring in non-Hodgkin's lymphomas: a critical reappraisal of molecular strategies.
    Corradini P; Ladetto M; Pileri A; Tarella C
    Leukemia; 1999 Nov; 13(11):1691-5. PubMed ID: 10557040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular remission and non-Hodgkin's lymphoma.
    Darby AJ; Johnson PW
    Best Pract Res Clin Haematol; 2002 Sep; 15(3):549-62. PubMed ID: 12468405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of molecular monitoring in autotransplantation for non-Hodgkin's lymphoma.
    Galimberti S; Marasca R; Caracciolo F; Fazzi R; Papineschi F; Benedetti E; Guerrini F; Morabito F; Oliva E; Di Renzo N; Federico M; Petrini M; Torelli G;
    Bone Marrow Transplant; 2002 Apr; 29(7):581-7. PubMed ID: 11979307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of minimal residual disease in lymphoid malignancies.
    Brüggemann M; Pott C; Ritgen M; Kneba M
    Acta Haematol; 2004; 112(1-2):111-9. PubMed ID: 15179011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal residual disease in non-Hodgkin lymphoma - current applications and future directions.
    Chase ML; Armand P
    Br J Haematol; 2018 Jan; 180(2):177-188. PubMed ID: 29076131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-time t(11;14) and t(14;18) PCR assays provide sensitive and quantitative assessments of minimal residual disease (MRD).
    Olsson K; Gerard CJ; Zehnder J; Jones C; Ramanathan R; Reading C; Hanania EG
    Leukemia; 1999 Nov; 13(11):1833-42. PubMed ID: 10557059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Contamination with minimal residual disease in autologous peripheral stem cell collected from Non-Hodgkin's lymphoma patients treated with high-dose therapy].
    Zhou A; Shi Y; Feng F; Lu S; He X; Han X
    Zhonghua Zhong Liu Za Zhi; 2002 Sep; 24(5):467-70. PubMed ID: 12485501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of minimal residual disease by polymerase chain reaction in B cell malignancies.
    Moos M; Schulz R; Cremer F; Sucker C; Schmohl D; Döhner H; Goldschmidt H; Haas R; Hunstein W
    Stem Cells; 1995 Dec; 13 Suppl 3():42-51. PubMed ID: 8747988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does MRD have a role in the management of iNHL?
    Giudice ID; Starza ID; Foà R
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):320-330. PubMed ID: 34889425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimal residual disease in non-Hodgkin's lymphoma.
    Schultze JL; Gribben JG
    Biomed Pharmacother; 1996; 50(9):451-8. PubMed ID: 8991117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring disease in lymphoma and CLL patients using molecular techniques.
    Gribben JG
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):179-95. PubMed ID: 11987923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stance of MRD in Non-Hodgkin's Lymphoma and its upsurge in the novel era of cell-free DNA.
    Garg S; Kumar A; Gupta R
    Clin Transl Oncol; 2021 Nov; 23(11):2206-2219. PubMed ID: 33991328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Droplet Digital PCR for Minimal Residual Disease Detection in Mature Lymphoproliferative Disorders.
    Drandi D; Ferrero S; Ladetto M
    Methods Mol Biol; 2018; 1768():229-256. PubMed ID: 29717447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of T-cell receptor delta gene rearrangement in T-cell malignancies by clonal specific polymerase chain reaction and its application to detect minimal residual disease.
    Chan DW; Liang R; Kwong YL; Chan V
    Am J Hematol; 1996 Jul; 52(3):171-7. PubMed ID: 8756082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR.
    Pott C; Brüggemann M; Ritgen M; van der Velden VHJ; van Dongen JJM; Kneba M
    Methods Mol Biol; 2019; 1956():199-228. PubMed ID: 30779036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical importance of semi-quantitative monitoring of lymphomas using the comparative polymerase chain reaction].
    Slavícková A; Ivánek R; Cerný J; Sálková J; Trnĕný M
    Cas Lek Cesk; 2002 Nov; 141(23):735-8. PubMed ID: 12650030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection and relevance of minimal disease in lymphomas.
    Sharp JG; Chan WC
    Cancer Metastasis Rev; 1999; 18(1):127-42. PubMed ID: 10505551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The biological markers of non-Hodgkin's lymphomas: their role in diagnosis, prognostic assessment and therapeutic strategy.
    Morra E
    Int J Biol Markers; 1999; 14(3):149-53. PubMed ID: 10569136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using the bioView (Duet) combined morphological and cytogenetical analysis.
    Shimoni A; Nagler A; Kaplinsky C; Reichart M; Avigdor A; Hardan I; Yeshurun M; Daniely M; Zilberstein Y; Amariglio N; Brok-Simoni F; Rechavi G; Trakhtenbrot L
    Leukemia; 2002 Aug; 16(8):1413-8; discussion 1419-22. PubMed ID: 12145678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rearranged immunoglobulin light chain genes as minimal residual disease markers in intermediate- and high-grade malignant B cell non-Hodgkin's lymphoma.
    Hoogeveen-Westerveld M; Hupkes PE; Doekharan D; Dorssers LC; van't Veer MB; van Belzen N
    Leukemia; 1998 Nov; 12(11):1810-6. PubMed ID: 9823958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.